Blinatumomab Improves Survival in Children with Standard-Risk B-ALL

by

New Treatment Significantly Improves Survival Rates for Children with Standard-Risk B-ALL

Philadelphia, PA – A groundbreaking new study suggests innovative immunotherapy drug blinatumomab coupled with chemotherapy significantly improves survival rates in children diagnosed with standard-risk (SR) B-acute Lymphoblastic Leukemia (ALL

Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

No. 6 Virginia Sweeps No. 11 Dartmouth 9-0

Tokyo Toni Slams Khloé Kardashian Over Thanksgiving Charity Clash

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.